Volume 115, Nº 1, July 2020
DOI: https://doi.org/10.36660/abc.20200530
SHORT EDITORIAL
Drug-Eluting Stents for Everyone: Is the Price Worth It?
Marcos Danillo P. Oliveira
Vanessa Teich
Adriano Caixeta
Keywords: Myocardial Infarction; Percutaneous Coronary Intervention; Drug-Eluting Stents; Coronary Reestenosis; Unified Health System (SUS); Cost-Benefit Analysis.